



VIA FACSIMILE

August 7, 2006

Christian Varin, Manager, Anti-Doping Services
Union Cycliste International
Ch 1860 Aigle
Switzerland

Board of Directors

Ralph W. Hale, MD
Chair

Richard W. Cohen, MD
Vice Chair

Barry Axelrod
Treasurer

Kate Hendrickson Borg, CHMM
Secretary

Evelyn Ashford

Lawrence Brown, Jr., MD, MPH

Jean Fourcroy, MD, PhD, MPH

Andrew Mecca, Dr PH, MPH

Annette Salmeen, DPhil

RE: UCI File No. 29/06
Tour de France, July 20, 2006
Floyd Landis – Sample #995474

Dear Mr. Varin:

I am in receipt of your letter dated August 5, 2006, forwarding the B sample laboratory results concerning the above referenced case.

As I indicated in my letter of July 31, 2006, the United States Anti-Doping Agency ("USADA") handles the adjudication of potential anti-doping violations in the United States. We have informed the athlete, USA Cycling and the United States Olympic Committee that we will proceed with the above referenced case under the USADA Protocol for Olympic Movement Testing.

At this time, please forward to us as soon as possible the laboratory documentation supporting the finding. I have enclosed, by way of an example, a list of laboratory documents that we typically receive. As you are probably aware, once we receive the laboratory documents, we will forward those to the athlete and notify him that he has ten (10) days to respond in writing. Following that time, an independent anti-doping review board will consider the matter and make a recommendation whether there is sufficient evidence of doping to proceed with the adjudication process. Given this, the sooner we receive the laboratory documents concerning the analysis, the sooner we can begin the ten (10) day time period for the case to be presented to the review board.

Additionally, given that the laboratory results include an elevated testosterone/epitestosterone ratio, please forward to us as soon as possible all prior and any subsequent test results, including the steroid profiles, from this athlete.


United States Anti-Doping Agency

1330 Quail Lake Loop, Suite 260, Colorado Springs, CO 80906 ■ Tel: 719.785.2000 ■ Fax: 719.785.2001

usada@usantidoping.org ■ www.usantidoping.org

If you have any questions or concerns, about this matter please do not hesitate to contact me. We look forward to your prompt reply.

Sincerely,

A handwritten signature in black ink, appearing to read "Travis T. Tygart", is written over a horizontal line.

Travis T. Tygart
General Counsel

cc: Sean Petty, USA Cycling
Janie Soubliere, WADA
Gary Johansen, USOC Deputy General Counsel
Jim Scherr, USOC Chief Executive Officer
Mr. Howard Jacobs, Counsel for Mr. Landis

ANNEX D

The following documentation will be supplied as the standard documentation package:

Table of contents

List of laboratory staff involved in the test, including signatures and/or initials and position title(s)

Sample identification information

Organization requesting the test

Date of sample collection and site identification

USADA sample identification number

Laboratory sample identification number

Urine Integrity test results (if completed)

Chain of custody documentation for sample container

Doping Control Notification form (Laboratory copy)

Transportation chain of custody (e.g., courier documentation, laboratory receipt of container)

"A" sample container chain(s) of custody

Documentation of any deviations from the written screening procedures, if any

"A" Sample Screening Results

Relevant aliquot chain(s) of custody

Screening procedure data, including chromatograms (or other relevant data), for Negative control urine

Positive control urine (with concentration indicated, if relevant)

Sample urine aliquot(s)

Analytical run instrument validation data (e.g., tune data)

Documentation of any deviations from the written screening procedures, if any

"A" Sample Confirmation Results

Summary of the analytical principles of the confirmation method

Aliquot chain of custody

Sequence verification data

Confirmation procedure data, including chromatograms (or other relevant data), for

Negative control urine

Positive control urine (with concentration indicated, if relevant)

Standard(s)/calibrator(s) (if relevant)

Sample urine aliquot(s)

Analytical run instrument validation data (e.g., tune data)

"A" sample report (including numerical data for threshold substances*)

pH, Specific Gravity, and other urine Integrity test results (if applicable,

including abnormal appearance of sample) performed in laboratory.

Documentation of any deviations from the written screening procedures, if any

"B" Sample Confirmation Results

"B" sample container chain(s) of custody

Summary of the analytical principles of the confirmation method (if different than "A")

Aliquot chain of custody

Sequence verification data

Confirmation procedure data, including chromatograms (or other relevant data), for

Negative control urine

Positive control urine (with concentration indicated, if relevant)

Standard(s)/calibrator(s) (if relevant)

Sample urine aliquot(s)

Analytical run instrument validation data (e.g., tune data)

"B" sample report (including numerical data for threshold substances*)

Documentation of any deviations from the written screening procedures, if any

Reports and Correspondence

All facsimiles or letters related to analysis and reporting of sample results

*For threshold substances, an estimate of the ratio or concentration or an estimate of the concentration relative to the threshold i.e. 20 times the threshold concentration) is deemed acceptable.